omniture
logo
Search
江苏先声药业有限公司 SIMCERE PHARMACEUTICAL GROUP
Media Room

Photo News

rss
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

2025-01-13 22:05 2873
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

2024-12-04 18:10 2506
World Stroke Congress | TASTE-2 significantly reduces stroke disability

World Stroke Congress | TASTE-2 significantly reduces stroke disability

2024-10-30 15:36 2226
TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

2024-10-25 15:14 2149
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

2024-09-14 19:43 4410
Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

2024-05-21 15:52 1887
Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

2024-02-21 12:26 3057
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

2023-11-23 16:04 5115
SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

2022-05-18 11:56 2554
SIMCERE PHARMA (HK.2096) to host 2022 R&D Day

SIMCERE PHARMA (HK.2096) to host 2022 R&D Day

2022-04-07 21:39 2969
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals

Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals

2022-02-08 10:01 2194